University of Ioannina
Mελέτη κλινικοπαθολογοανατομικών και ανοσοϊστοχημικών παραμέτρων με προβλεπτική και προγνωστική αξία στο καρκίνωμα αγνώστου πρωτοπαθούς εστίας (ΚΑΠE) και ανάπτυξη προγνωστικού αλγόριθμου
Abstract
dc:descriptionBackground: CUP represents a heterogeneous population of patients with systemicmalignancy, variable outcomes and managed on the basis of ‘‘one size fits all’’therapeutic concepts.Identification of clinical, pathologic and laboratory parameters with prognostic utilitycould contribute to estimation of death hazard and tailoring of therapy. Also insightsinto the molecular biology of CUP are urgently needed.Patients and Methods: Our study is divided in two parts. In the first part, clinical,pathologic and laboratory data from 311 patients with CUP diagnosed in a singleuniversity centre from 1988 to 2011 were examined for prognostic significance inunivariate, multivariate and Classification and Regression Tree (CART) analyses. Weanalysed all published CUP prognostic algorithms in PubMed and EmBase from 1985to date in order to describe defining characteristics.We also retrospectively examined in the second part the immunohistochemical (IHC) expression of PTEN, phospho-AKT, Cyclin D1, p21, phospho-RPS6, Notch1, 2,3, Jagged1, cMET, and pMAPK biomolecules in 100 CUP tumors using tissuemicroarrays. From the percentage of staining tumour cells and the literature, we selectedcut-offs to classify the expression of each biomolecule, aiming to study their correlationto clinicopathologic characteristics and prognostic utility for patient outcome.Results: In the 311 patients which were examined for the development of a prognosticalgorithm, most patients harboured poorly differentiated adenocarcinoma or carcinoma(85%) in visceral sites (62%) and were managed with combination chemotherapy.Median overall survival for all patients was 8 months (95% CI 6.7–9.1). Multivariateanalysis established that only leucocytosis (HR 0.37, p = 0.001, cut off <10,000/mm3 leucocytes), clinicopathologic CUP subgroup (HR 2.44, p = 0.001 for the visceralsubgroup) and performance status (HR 0.58, p = 0.002 for PS 0–1) retained independent prognostic significance. These three parameters were used for developinga prognostic algorithm (Ioannina Score for CUP Outpatient Oncologic Prognostication,I-SCOOP) which produced a dynamic 5-tier point score and classified patients in low,intermediate and high risk groups with median survival times of 36, 11–14 and 5–8months respectively.The immunoistochemical analysis of the 100 CUP patients showed thatPTEN, pAKT, pRPS6, Notch3, and pMAPK were frequent expressed. At univariateanalysis, high IHC expression of pAKT and pRPS6 displayed statistically significantassociation with worse survival. Prognosis was worse upon concurrent high IHCexpression of pMAPK and pAKT {median overall survival = 8 months [95%confidence interval (CI) 5.3-10.7] versus 17 months [95% CI 13.1-20.9]}. Inmultivariate analysis, high p21 was associated with better survival (risk ratio [RR] =0.34 [95% CI 0.16-0.73], P = 0.005). High expression of pAKT (RR = 2.39 [95% CI1.23-4.66], P = 0.01) or pRPS6 (RR = 2.76 [95% CI 1.31-5.84], P = 0.008) wasassociated with worse survival. A linear correlation of Notch3 and cMET expression was found (p = 0.001), while pMAPK emerged as the major adverse prognostic factor(median overall survival OS 9 vs. 17 months, p = 0.016), carrying also a significantlypositive predictive value (p = 0.02). Our study indicated a favorable prognostic impactof cMET expression in CUP, both in univariate (median OS 15 vs. 9 months, p = 0.05)and in multivariate analysis (Relative Risk RR for death 0.48, p = 0.025). cMET andNotch3 expression were found to be statistically more frequent in squamous carcinomas(positive in 90 % of cases), associated with a unique metastatic IHC pattern (cMEThighin soft tissue/lymph node metastases, p\0.001, Notch3-high in visceral,peritoneal/pleural and soft tissue/lymph node metastases, p\0.001).Conclusions: We developed a simple and easy to use CUP prognostic algorithm basedon readily available clinicopathologic and laboratory variables. A major limitation ofmost studies on CUP prognostic scores is the inability to proceed to prospective orretrospective validation of the algorithm in an independent CUP patient population.However, intrinsic statistical validation generated promising, though not definite, hints that our model is stable and independent of random population and data fluctuationsOur preliminary data pinpoint the MAPK and cMET axes as crucial in definingcancer progression and outcome in CUP patients and, if prospectively validated inindependent series, could identify these biomolecules as promising therapeutic targets.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Petrakis, Dimitrios
- Πετράκης, Δημήτριος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39612